U.S. Markets closed

Dynavax Reports Third Quarter 2017 Financial Results

BERKELEY, CA--(Marketwired - November 03, 2017) - Dynavax Technologies Corporation (DVAX) today reported financial results for the third quarter ended September 30, 2017. Cash, cash equivalents and marketable securities were $191.7 million at September 30, 2017 compared to $81.4 million at December 31, 2016. The increase was primarily due to net proceeds of approximately $169 million during the year from an underwritten public offering and sales of common stock under an at-the-market sales agreement.

Additional Financial Results

The net loss for the three months ended September 30, 2017 was $22.1 million, or $0.38 per share, compared to $34.7 million, or $0.90 per share, for the same period in 2016. The net loss for the nine months ended September 30, 2017 was $67.7 million, or $1.36 per share, compared to $90.7 million, or $2.36 per share, for the same period in 2016.

Research and development expenses for the quarter and nine months ended September 30, 2017 were $16.4 million and $47.6 million, respectively, compared to $23.2 million and $66.1 million for the same periods in 2016. The decrease in the 2017 periods reflect reduced compensation and related personnel costs as a result of the January 2017 restructuring and cost reduction initiative. Additionally, the 2017 periods reflect lower costs related to the investigational product HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] clinical and manufacturing activity partially offset by increased costs relating to seeking FDA approval for HEPLISAV-B and the ongoing development of SD-101, DV281 and earlier stage oncology programs.

General and administrative expenses for the quarter and nine months ended September 30, 2017 were $6.0 million and $18.1 million, respectively, compared to $11.8 million and $29.1 million for the same periods in 2016. The decrease in the 2017 periods reflect reduced compensation and related personnel costs as a result of the January 2017 restructuring and cost reduction initiative. Additionally, the 2016 periods included costs related to hiring of consultants for administrative and commercial development services for an anticipated commercial launch of HEPLISAV-B following FDA approval of this investigational product.

About HEPLISAV-B

HEPLISAV-B is an investigational adult hepatitis B vaccine that combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist. Data from the Phase 3 trials which evaluated HEPLISAV-B administered as a two dose regimen over one month as compared to a currently licensed hepatitis B vaccine administered as 3 doses over a six month period are currently under review by FDA. Dynavax's Biologics License Application for HEPLISAV-B has a Prescription Drug User Fee Act date of November 9, 2017. Dynavax has worldwide commercial rights to HEPLISAV-B.

About SD-101

SD-101 is Dynavax's proprietary, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide. SD-101 is being studied for its multiple anti-tumor activities in innate immune cells and activation of plasmacytoid dendritic cells to stimulate T cells specific for antigens released from dying tumor cells. TLR9 agonists such as SD-101 enhance T and B cell responses and provide potent Type 1 interferon induction and maturation of plasmacytoid dendritic cells to antigen-presenting cells. SD-101 is being evaluated in several Phase 1/2 oncology studies to assess its safety and activity.

About DV281

DV281 is Dynavax's proprietary investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV281 is similar in biological activity and mechanism of action to Dynavax's Phase 2 immunotherapy candidate, SD-101, but has been optimized for administration as an aerosol. Both SD-101 and DV281 activate plasmacytoid dendritic cells which then stimulate T cells specific for antigens released from dying tumor cells. TLR9 agonists such as DV281 and SD-101 have been shown to stimulate potent Type 1 interferon induction along with maturation of dendritic cells to effective antigen-presenting cells; both activities are important for the induction of effective anti-tumor immunity. Dynavax has initiated dosing in a phase 1B dose escalation clinical trial of DV281 in patients with non-small cell lung cancer.

For information about SD-101 and DV281 trials that are currently recruiting patients, please visit www.clinicaltrials.gov.

About Dynavax

Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates for use in multiple cancer indications and a vaccine for the prevention of hepatitis B. Dynavax's lead product candidates are SD-101 and DV281, investigational cancer immunotherapeutics currently in Phase 1 and Phase 2 studies, and HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine. For more information, visit www.dynavax.com.

Forward Looking Statements

This release contains forward-looking statements and estimates. These statements are subject to a number of risks and uncertainties that could cause actual results to differ materially, including whether the FDA will approve HEPLISAV-B, notwithstanding the FDA Advisory Committee votes in favor of the efficacy and safety of HEPLISAV-B; whether additional studies or manufacturing process enhancements will be required, or other issues will arise that will delay the BLA review or negatively impact the review and decision whether to approve HEPLISAV-B; the nature and scope of the post-marketing pharmacovigilance plan for HEPLISAV-B; the final label claims and the nature of the label content for HEPLISAV-B; whether we will be able to timely develop the required commercial infrastructure to successfully launch HEPLISAV-B; whether manufacturing issues will arise that will impact our ability to have an adequate supply of HEPLISAV-B to meet demand; whether the ACIP will recommend use of HEPLISAV-B and the timing of receiving a recommendation; whether we can timely provide adequate clinical supplies; initiation, enrollment and completion of clinical trials of SD-101 of DV281; the results of clinical trials and the impact of those results on the initiation or continuation of subsequent trials and issues arising in the regulatory process; the ability to successfully develop and commercialize SD-101 and DV281; whether or not Dynavax and parties with whom we are collaborating may reach any future agreement on further studies or a more extensive collaboration beyond the clinical trials contemplated under the existing agreements; and other risks detailed in the "Risk Factors" section of our most recent periodic report filed with the SEC. These statements represent our estimates and assumptions only as of the date of this press release. We do not undertake any obligation to update publicly any such forward-looking statements, even if new information becomes available. Information on Dynavax's website at www.dynavax.com is not incorporated by reference in our current periodic reports with the SEC.

 
DYNAVAX TECHNOLOGIES CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
 
  Three Months Ended   Nine Months Ended
  September 30,   September 30,
  2017     2016     2017     2016  
Revenues:                              
  Collaboration revenue $ -     $ -     $ -     $ 2,578  
  Grant revenue   53       162       306       289  
  Service and license revenue   -       -       -       884  
Total revenues   53       162       306       3,751  
                               
Operating expenses:                              
  Research and development   16,417       23,234       47,576       66,051  
  General and administrative   6,027       11,766       18,111       29,086  
  Restructuring   -       -       2,783       -  
Total operating expenses   22,444       35,000       68,470       95,137  
                               
Loss from operations   (22,391 )     (34,828 )     (68,164 )     (91,386 )
                               
Interest income   429       170       809       615  
Other income (expense), net   (166 )     (26 )     (378 )     68  
Net loss $ (22,128 )   $ (34,694 )   $ (67,733 )   $ (90,703 )
Basic and diluted net loss per share $ (0.38 )   $ (0.90 )   $ (1.36 )   $ (2.36 )
Weighted average shares used to compute basic and diluted net loss per share   57,650       38,512       49,785       38,493  
 
 
DYNAVAX TECHNOLOGIES CORPORATION
SELECTED BALANCE SHEET DATA
(In thousands)
(Unaudited)
 
    September 30,   December 31,
    2017   2016
Assets        
  Cash, cash equivalents and marketable securities   $191,680   $81,415
  Property and equipment, net   16,622   17,174
  Goodwill   2,213   1,971
  Other assets   7,312   9,120
Total assets   $217,827   $109,680
         
Liabilities and stockholders'equity        
  Other liabilities   13,393   20,479
  Total liabilities   13,393   20,479
  Stockholders' equity   204,434   89,201
Total liabilities and stockholders' equity   $217,827   $109,680
  • Suze Orman has a killer question for your retirement
    Business
    MarketWatch

    Suze Orman has a killer question for your retirement

    Suze Orman is one of those singular personalities in the financial business who seems to be right on the pulse of everyone she meets. She’s written books, starred in her own television show and made innumerable appearances in person. Like Oprah

  • Suddenly Toxic, Saudi Prince Is Shunned by Investors He Courted
    World
    Bloomberg

    Suddenly Toxic, Saudi Prince Is Shunned by Investors He Courted

    Now Crown Prince Mohammed bin Salman could become the biggest risk to his own project. Everything changed when Jamal Khashoggi walked into the Saudi consulate in Istanbul on Oct. 2 and didn’t come out. Prince Mohammed, who’s denied any knowledge of Khashoggi’s fate, still has his defenders -– notably Donald Trump.

  • Why Advanced Micro Devices, Inc. Stock Closed 11% Lower on Friday
    Business
    Motley Fool

    Why Advanced Micro Devices, Inc. Stock Closed 11% Lower on Friday

    Analyst Pierre Ferragu from financial firm New Street Research set his price target for AMD at $18 per share, arguing that the stock has been priced for a level of success that simply isn't realistic. "AMD's stock price reflects a scenario we don't believe possible," Ferragu wrote. In particular, Ferragu sees larger rival Intel (NASDAQ: INTC) getting its manufacturing act together as we speak.

  • Marijuana investors may lose 90% of their money in Canada, so consider the really big prize elsewhere
    News
    MarketWatch

    Marijuana investors may lose 90% of their money in Canada, so consider the really big prize elsewhere

    Marijuana presents a tremendous opportunity for investors over the next few years. Naïve investors are excited. The reality is that professionals will pick their pockets, and many naïve investors who are excited now will end up losing 90% of their investment.

  • Looks like when millennials have some money, they get an ...
    AXP
    CNBC Videos

    Looks like when millennials have some money, they get an ...

    CNBC's 'Squawk on the Street' team discusses markets ahead of the market open.

  • Tesla slides after Elon Musk announced lower-cost Model 3 (TSLA)
    Business
    Business Insider

    Tesla slides after Elon Musk announced lower-cost Model 3 (TSLA)

    Tesla CEO Elon Musk announced on Twitter on Thursday that a lower-cost Model 3 was immediately available for order on the company's website. The electric car will have a base price of $45,000 and is eligible for federal and state tax rebates. Tesla shares were down more than 3% Friday after — they gained as much as 2.2% earlier in the session.

  • Why Valero Energy, eBay, and New Age Beverages Slumped Today
    Business
    Motley Fool

    Why Valero Energy, eBay, and New Age Beverages Slumped Today

    Some major market benchmarks managed to hang onto their gains, but the Nasdaq Composite, and Russell 2000 indexes posted losses of 0.5% to 1.25%, and the S&P 500 was virtually flat. Valero Energy (NYSE: VLO), eBay (NASDAQ: EBAY), and New Age Beverages (NASDAQ: NBEV) were among the worst performers on the day. Valero Energy dropped 10% after the refinery company announced that it would buy back all outstanding units of its related MLP, Valero Energy Partners (NYSE: VLP).

  • Business
    Investopedia

    Market Sell-Off 80% Over, Will Be Reversed by Stock Repurchases: JPMorgan

    Last week, global markets were hit with a widespread shock that weighed on nearly all asset classes, encompassing even the cryptocurrency space, once viewed as a type of "safe haven" bet unrelated to the broader market. In a note to clients on Thursday, JPMorgan equity strategist Dubravko Lakos-Bujas and team forecasted for U.S. equities to make a comeback as fundamentals come back into play, highlighting stock buybacks as a key driver of the nine-year-bull market, as reported by CNBC.

  • Hate Taxes? 37 States Make Social Security Tax Free
    Business
    Motley Fool

    Hate Taxes? 37 States Make Social Security Tax Free

    Over the course of your career, you'll probably have tens of thousands of dollars in Social Security payroll taxes withheld from your paychecks. Workers are confident that by paying those taxes up front, they'll be able to collect Social Security benefits

  • 7 Breakout Stocks to Buy That Are “Immune” to Volatility
    Finance
    InvestorPlace

    7 Breakout Stocks to Buy That Are “Immune” to Volatility

    With another disappointing session for the Dow Jones, investors are scrambling to find answers. More than likely, President Donald Trump will face a split government, which may yield increased volatility in Washington. Just recently, Wall Street tumbled when Treasury Secretary Steven Mnuchin decided to withdraw from an investment conference with Saudi Arabia.

  • 3 Energy Stocks You Can Buy and Hold for the Next Decade
    Business
    Motley Fool

    3 Energy Stocks You Can Buy and Hold for the Next Decade

    North America needs to build $23 billion of new natural gas-related infrastructure annually through 2035, according to a recent report. Three of the best positioned to capture this growth are Kinder Morgan (NYSE: KMI), Williams Companies (NYSE: WMB), and TransCanada (NYSE: TRP), making them great stocks to buy and hold in the coming decade. Kinder Morgan is already the largest natural gas pipeline company in North America, operating roughly 70,000 miles of pipeline.

  • China’s Problems Keep Piling Up With Trump, Economy, and Markets
    Business
    Bloomberg

    China’s Problems Keep Piling Up With Trump, Economy, and Markets

    A day after the Shanghai Composite Index plunged to a four-year low and Trump took new steps to escalate his trade war with Beijing, third-quarter growth figures showed China’s economy expanding at the weakest pace since the depths of the global financial crisis in 2009. Economic policy makers including Vice Premier Liu He, who also weighed in on Friday, are now left walking a tightrope.

  • 3 Things Netflix Management Wants Investors to Know
    Business
    Motley Fool

    3 Things Netflix Management Wants Investors to Know

    Netflix (NASDAQ: NFLX) had a monster third quarter. The streaming giant bounced back from its disappointing second quarter (in which it still added 5.45 million paying subscribers) to exceed its Q3 projections by adding 6.15 million new subscribers. The

  • Should Congress cut entitlement programs to combat rising deficit?
    Politics
    Fox Business Videos

    Should Congress cut entitlement programs to combat rising deficit?

    Maya MacGuineas, Committee for a Responsible Federal Budget, and Wall Street Journal editorial page deputy editor James Freeman discuss America’s deficit problem and how President Trump asked members of his Cabinet to cut their departments’ budgets by 5 percent.

  • Will Cloud and Improving Margins Dominate Amazon's Earning Report?
    Business
    Motley Fool

    Will Cloud and Improving Margins Dominate Amazon's Earning Report?

    Part of what drove the company to those dizzying heights was the impressive results Amazon has produced so far this year. The company grew revenue an impressive 41% year over year in the first half of 2018, but Amazon Web Services (AWS) is doing even better, up 48% compared to the first six months of last year. All signs point to another strong performance when Amazon reports the financial results of its third quarter after the market close on Thursday, Oct. 25, but let's look at Amazon's most recent results and see what the company will need to do to continue its upward momentum.

  • Don’t cheat yourself with the 4% rule
    Business
    MarketWatch

    Don’t cheat yourself with the 4% rule

    If you’re planning for retirement, you’re probably thinking about how much you’ll need, how long the money will last, and how much you can safely take out each year. You recognize that in retirement there will be a balancing act between spending on current needs while also preserving enough for your later years. Instead, all-too-often, retirees use simplified rules of thumb to determine how much to take out each year.

  • 1 Top Stock to Buy Amid October’s Turbulent Market
    Business
    Motley Fool

    1 Top Stock to Buy Amid October’s Turbulent Market

    In the past three weeks alone, stocks have tumbled about 5%, which has many investors unnerved. One top option to consider amid the current turbulence is Magellan Midstream Partners (NYSE: MMP), which has lost more than 5% of its value in the past few weeks. Because of that, investors can get an even better starting price on one of the top master limited partnerships (MLPs), potentially setting themselves up to earn market-beating returns in the coming years.

  • Marijuana stocks to watch: Aurora Cannabis investments may be more valuable than its pot
    News
    MarketWatch

    Marijuana stocks to watch: Aurora Cannabis investments may be more valuable than its pot

    Aurora Cannabis Inc. is a major pot producer, but if its bets on other cannabis companies continue to pay off, it may be able to stop actually growing weed on its own. Aurora (ACBFF)(CA:ACB) said recently its investments were worth more than C$700 million ($540 million) as of Sept. 21, bolstered in part by demand for pot stocks ahead of full legalization of marijuana in Canada on Wednesday. As the entire sector has benefited, so has Aurora’s portfolio, boosting the company’s fiscal fourth-quarter profit to C$79.9 million, after a loss of $20.8 million the year earlier.

  • This Refining Giant Is the Latest Energy Company to Give Up on Its MLP
    Business
    Motley Fool

    This Refining Giant Is the Latest Energy Company to Give Up on Its MLP

    The energy sector continues to experience a gigantic consolidation wave, which is causing master limited partnerships (MLPs) to drop like flies. Valero Energy (NYSE: VLO) is behind the latest disappearing act in the space after it agreed to buy out its MLP Valero Energy Partners (NYSE: VLP). Valero Energy launched Valero Energy Partners in late 2013, joining its refining rivals in creating an income-producing vehicle that would steadily buy its parent's midstream assets.

  • Colorado’s Marijuana Market Just Hit This Huge Milestone
    Business
    Motley Fool

    Colorado’s Marijuana Market Just Hit This Huge Milestone

    Marijuana has been legally available in Colorado for recreational use since 2014, and consumers' appetite for marijuana products continues to grow due to the launch of new products, including concentrates and edibles. As a result, Colorado's annual marijuana sales surpassed $1 billion in August -- the earliest it has ever achieved that milestone. There's been some debate over how much money would move from the black market to regulated markets following legalization, but Colorado's experience suggests it's substantial.

  • America’s Biggest Employer Isn’t Hiring Seasonal Employees This Year. Here’s the Reason Why
    Business
    Money

    America’s Biggest Employer Isn’t Hiring Seasonal Employees This Year. Here’s the Reason Why

    For the third year, Walmart won’t be hiring tens of thousands of seasonal employees to provide extra support during the holidays. Instead, Walmart is forgoing the long-standing practice in favor of giving it’s full- and part-time employees more hours and opportunities to earn extra cash. The idea, Walmart says, is to fulfill the wishes of many of its employees.

  • This Marijuana Investment Firm's 11 Top Cannabis Picks for Explosive Growth
    Business
    Motley Fool

    This Marijuana Investment Firm's 11 Top Cannabis Picks for Explosive Growth

    The marijuana industry has become a hotbed of investment activity, and players of all sizes are looking to get into the action. On top of all the interest from ordinary investors, cannabis companies have seen demand rise from sophisticated institutional investors that have experience with deploying larger amounts of investment capital in search of high-growth opportunities. One of the most interesting marijuana investment specialists that investors can follow is Canopy Rivers (NASDAQOTH: CNPOF).

  • Marijuana stocks to watch: Canopy Growth is the cannabis business’s $4 billion gorilla
    News
    MarketWatch

    Marijuana stocks to watch: Canopy Growth is the cannabis business’s $4 billion gorilla

    The following article is part of a package of stories that MarketWatch is publishing to mark the start of full legalization of cannabis for adult use in Canada on Wednesday. Smith Falls, Ontario–based Canopy Growth Corp. made headlines and drove cannabis stocks to new heights over the summer when it announced that Corona brewer Constellation Brands Inc. was going to invest an additional $4 billion in the company. Billed by both companies as a strategic partnership, the additional $4 billion investment adds to the 9.9% stake that Constellation bought in October of last year and sets the company up to either be bought outright by Constellation — via warrants that could increase its stake to more than 50% — or continue to work with the beverage company to create a range of consumer-focused cannabis products that may one day appear in markets in dozens of countries.

  • Now is a ‘once-in-a-lifetime’ chance to invest in US pot companies, investor says
    Finance
    Yahoo Finance

    Now is a ‘once-in-a-lifetime’ chance to invest in US pot companies, investor says

    With some Canadian pot stocks posting triple-digit return rates this year, many retail investors have looked north to pour cash into cannabis. U.S. cannabis companies are worth a lot more than their current valuations suggest since federal illegality has put undue pressure on the industry, said David Wenger, a New York attorney and senior editor of the Cannabis Law Digest.

  • Tech Stocks This Week: Volatility Strikes Again
    Finance
    Motley Fool

    Tech Stocks This Week: Volatility Strikes Again

    In another volatile week, many tech stocks made some big moves over the past five trading days. Notably, streaming-TV giant Netflix (NASDAQ: NFLX) and financial-technology company PayPal Holdings (NASDAQ: PYPL) both saw their shares jump sharply after their earnings releases. Netflix stood out with its surging subscriber growth, while PayPal made headlines with its strong momentum in its peer-to-peer payment app, Venmo.